Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors
28.2.2019 00:10:03 CET | LEO Pharma | Press release
At the Annual General Meeting in LEO Holding A/S on February 26th a unified Board of Directors elected former vice chairman Olivier Bohuon as new chairman of the Board of Directors of LEO Pharma following Jukka Pertola’s decision to leave the Board. Anders Ekblom was elected as new vice chairman. In addition, John Weeks decided to not seek
re-election.
“With Olivier Bohuon and Anders Ekblom we have two strong successors with extensive industry experience who can help set the direction for LEO Pharma’s future development and realize the company’s ambitious strategy towards 2025. Olivier Bohuon has profound knowledge from several leading positions in the global pharma industry and Anders Ekblom’s scientific background and comprehensive experience from the global life science sector is an ideal complement”, said Jukka Pertola, resigning chairman of LEO Pharma.
Jukka Pertola has been member of LEO Pharma’s Board of Directors since 2011 and chairman since 2016.
“Jukka Pertola has been instrumental in getting LEO Pharma to the position the company holds today and by manning the board with strong profiles and securing board succession. During his time as member and chairman of the Board of Directors, LEO Pharma has gone through a massive transformation turning the company into a global leader specialized in medical dermatology. I would like to express my sincere gratitude to Jukka for his contribution”, said Lars Olsen, chairman of the Board of Trustees of the LEO Foundation, also thanking John Weeks for his dedicated contribution as member of the Board of Directors at LEO Pharma since 2014.
Olivier Bohuon is External Director of the Board of Directors at Takeda plc, External Director of the Board of Directors of Smiths Group plc, a supervisory board member at Virbac SA, and member of the French National Pharmacy Academy and the French Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew Plc. Before that, he held positions as CEO at Laboratories Pierre Fabre and President of Pharmaceutical Products Division at Abbott Laboratories.
Anders Ekblom is a physician, board certified in anaesthesia and intensive care, dentist and Associate Professor in physiology at Karolinska Institute and a fellow of the Royal Swedish Academy of Engineering Sciences. His experience from the global biopharmaceutical industry includes positions as EVP Global Medicines Development at AstraZeneca Plc, CEO of AstraZeneca AB Sweden, Director of the Board at Mereo BioPharma Group Plc, Alligator Bioscience AB, and several other companies.
Contacts
Media Contacts
Head of Global External Communication
Henrik Kyndlev
hdtdk@leo-pharma.com
TEL +45 3140 6180
Corporate Communications Manager
Maia Fredtoft Soechting
mfddk@leo-pharma.com
TEL +45 3119 3559
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to:
www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma announces key results of Phase 2 TRAPEDS-1 trial evaluating pharmacokinetics and safety of tralokinumab in children with moderate-to-severe atopic dermatitis9.7.2026 17:00:00 CEST | Pressemeddelelse
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what has previously been observed with tralokinumab. Tralokinumab was generally well tolerated for up to 172 weeks of treatment, with no new safety signals identified.
LEO Pharma to showcase new data highlighting the burden and unmet needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen25.6.2026 13:00:00 CEST | Pressemeddelelse
New data show that chronic hand eczema can disrupt working lives and school days, with many patients reporting sick leave from work and worsening of symptoms during everyday activities.1 Findings from the DELTA FORCE and DELTA TEEN phase 3 studies highlight the heavy burden of chronic hand eczema across the life course – from impaired work productivity in adults to an impact on school life in adolescents.1,2
LEO Pharma’s net-zero and emissions reduction targets validated by SBTi8.6.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma has achieved Science Based Targets initiative (SBTi) validation for its net-zero climate targets, including its ambition to reach net-zero greenhouse gas emissions by 2050, alongside near-term goals to reduce Scope 1 and 2 emissions by 63% and Scope 3 emissions by 37.5% by 2035 With its targets now validated, LEO Pharma is shifting from target-setting to implementation, advancing 15 prioritized initiatives in its Climate Transition Plan while emphasizing the connection between environmental health and patient care
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom